EUROPEAN
COMMISSION

Brussels, XXX
PLAN/1871/2023 ANNEX
(POOL/E4/2023/1871/1871-EN
ANNEX.docx)
[…](2023) XXX draft

ANNEX

**ANNEX**

**to the**

**COMMISSION IMPLEMENTING REGULATION (EU) .../...**

**approving trihydrogen pentapotassium di(peroxomonosulfate) di(sulfate) as an existing active substance for use in biocidal products of product-types 2, 3, 4 and 5 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council**

## ANNEX

| Common Name | IUPAC Name Identification Numbers | Minimum degree of purity of the active substance[1] | Date of approval | Expiry date of approval | Product type | Specific conditions |
|---|---|---|---|---|---|---|
| Trihydrogen pentapotassium di(peroxomonosulfate) di(sulfate) | Pentapotassium bis((hydroperoxysulfonyl)oxidanide) hydrogen sulfate sulfate<br><br>EC No: 274-778-7<br><br>CAS No: 70693-62-8 | ≥ 890 g/kg (≥ 89 w/w)<br><br>dipotassium peroxydisulphate (relevant impurity): ≤ 20 g/kg (≤ 2 % w/w) | 1 July 2025 | 30 June 2035 | 2 | The authorisation of biocidal products is subject to the following conditions:<br>(1) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance;<br>(2) the product assessment shall pay particular attention to:<br>(i) professional users;<br>(ii) non-professional users;<br>(iii) surface water due to chronic emission following private swimming pool disinfection. |
| | | | | | 3 | The authorisation of biocidal products is subject to the following conditions:<br>(1) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance;<br>(2) the product assessment shall pay particular attention to professional users. |
| | | | | | 4 | The authorisation of biocidal products is subject to the |

[1] The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | following conditions:<br>(1) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance;<br>(2) the product assessment shall pay particular attention to professional users. |
| | | | | | 5 | The authorisation of biocidal products is subject to the following conditions:<br>(1) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance;<br>(2) the product assessment shall pay particular attention to professional users. |